Ventures Accelerated summarizes how the 2025 Nobel Prize in Physiology or Medicine, awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for discoveries in peripheral immune tolerance, is now paving the way for new treatments for autoimmune and inflammatory diseases.

Through an interview with Nobel laureate Fred Ramsdell and examples from companies including Diamyd Medical, the article illustrates how decades of T-cell research are being translated into precision therapies and new investment opportunities in chronic inflammation and autoimmunity. The article also features Karin Rosén, a member of the board of directors of Diamyd Medical, who provides the company’s perspective on how these scientific breakthroughs connect to the development of antigen-specific treatments for type 1 diabetes.

Read the article here